Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype.
about
Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - a reviewProfile of rifaximin and its potential in the treatment of irritable bowel syndromeRifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic DichotomyNew insights in IBS-like disorders: Pandora's box has been opened; a reviewPotential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview.Small intestinal bacterial overgrowth and celiac disease: A systematic review with pooled-data analysis.FFA2 activation combined with ulcerogenic COX inhibition induces duodenal mucosal injury via the 5-HT pathway in rats.Small Intestinal Bacterial Overgrowth in Patients with Refractory Functional Gastrointestinal Disorders.Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome.Small Intestinal Bacterial Overgrowth in Patients with Irritable Bowel Syndrome: Clinical Characteristics, Psychological Factors, and Peripheral CytokinesThe comparison of treatments with and without azithromycin in irritable bowel syndrome with diarrhea-predominant in gastrointestinal Clinic of Al-Zahra Hospital, Isfahan, Iran.Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders.Mucosal pathobiology and molecular signature of epithelial barrier dysfunction in the small intestine in irritable bowel syndrome.Enhancing High Value Care in Gastroenterology Practice.Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.Alterations of gut microbiota in patients with irritable bowel syndrome: A systematic review and meta-analysis.Progress in Our Understanding of the Gut Microbiome: Implications for the Clinician.Post-infectious IBS, tropical sprue and small intestinal bacterial overgrowth: the missing link.From clinical uncertainties to precision medicine: the emerging role of the gut barrier and microbiome in small bowel functional diseases.Irritable bowel syndrome in Asia: pathogenesis, natural history, epidemiology and management.Reduced interstitial cells of Cajal and increased intraepithelial lymphocytes are associated with development of small intestinal bacterial overgrowth in post-infectious IBS mouse model.Is irritable bowel syndrome an infectious disease?Role of Small Intestinal Bacterial Overgrowth in Functional Gastrointestinal Disorders.Short-chain fatty acid sensing in rat duodenum.Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile.Prevalence of abnormal lactose breath hydrogen tests in children with functional abdominal pain.Gut Microbiota-Based Therapies for Irritable Bowel Syndrome.Pharmabiotic Manipulation of the Microbiota in Gastrointestinal Disorders: A Clinical Perspective.Effects of Alkaline-Reduced Drinking Water on Irritable Bowel Syndrome with Diarrhea: A Randomized Double-Blind, Placebo-Controlled Pilot Study.
P2860
Q26796416-DAA65F4B-9DF7-452A-9D53-CCAEC857221FQ26829363-9A4BC375-1556-43CB-9BFD-23F40B7FFA59Q33466527-860FE91B-178F-4802-9EAF-7F785088AA7AQ33469991-4A6C85CA-D0F1-4A40-BAE9-F2028006D497Q33867365-B8290994-2C3A-49D9-B133-60240EF84276Q35971357-8E0EEFB7-3A8D-4F19-AFB7-C3304D4E14DCQ36278242-2BA79043-F723-4CAD-87F6-6D7FC56BA60DQ36376786-C703CF19-085C-4F10-A1D5-2138D15EE044Q36426034-6886D6F7-4F78-4817-80E1-E4EED3F824BEQ36970524-48A94410-148B-47CF-8313-C857DC700313Q37030459-F510346E-8316-48EB-AF0C-225C002681EAQ37504612-FDCE8EC1-ED93-48DF-BBF8-056A93A389D9Q37564122-0E68BE51-E3D7-4F1A-A281-2F3D15BB53B7Q38810529-DEC3E023-A708-44C8-B51F-0BC782A0C23CQ38842110-5AD39366-783C-4A48-B7BD-AFDE3A43031DQ38856699-AD269FE1-9589-4D6A-A457-37A89EB0FAD4Q38864862-DD825B72-092B-4BAF-9215-6BD8F44DC845Q38905778-B9B6514B-8698-4750-87F6-77E5A105DBDBQ39022623-CC58A5DA-C656-4B5A-AC1C-D32998294996Q39376100-1A6DCE2B-EF17-426C-9005-54278C521579Q40044036-CB8B18C1-CF56-4C5A-A2F7-E3B78453CFBEQ40146780-26455EAD-65CA-40C4-85A1-6F10D9F147AAQ43075314-33DB5C8D-DA52-40BB-86E0-268517FDD13CQ43107093-4C3C5BA9-3644-4F72-A57D-70D1A2A20705Q46188862-2EF1DC43-ECF3-46B6-B1C9-A6CC45C261F7Q46319853-1344A471-1762-4B34-9DFF-E20F492F7524Q47869948-C8BDE37F-1836-42D6-8678-175426B62D05Q49985626-022314E9-AA1D-48D5-9136-5B4B6607AE0FQ52312388-5F93F019-140C-403F-A738-803DCB1941C3Q54985907-F2CFAA09-E982-4A7C-B047-A586DF4AB0BD
P2860
Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Irritable bowel syndrome and s ...... sociation or unnecessary hype.
@ast
Irritable bowel syndrome and s ...... sociation or unnecessary hype.
@en
Irritable bowel syndrome and s ...... sociation or unnecessary hype.
@nl
type
label
Irritable bowel syndrome and s ...... sociation or unnecessary hype.
@ast
Irritable bowel syndrome and s ...... sociation or unnecessary hype.
@en
Irritable bowel syndrome and s ...... sociation or unnecessary hype.
@nl
prefLabel
Irritable bowel syndrome and s ...... sociation or unnecessary hype.
@ast
Irritable bowel syndrome and s ...... sociation or unnecessary hype.
@en
Irritable bowel syndrome and s ...... sociation or unnecessary hype.
@nl
P2860
P356
P1476
Irritable bowel syndrome and s ...... sociation or unnecessary hype.
@en
P2093
Deepakshi Srivastava
P2860
P304
P356
10.3748/WJG.V20.I10.2482
P407
P577
2014-03-01T00:00:00Z